Who are Losartan and nebivolol's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/losartan-and-nebivolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Losartan and nebivolol — Competitive Intelligence Brief

Losartan and nebivolol (Losartan and nebivolol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist + selective beta-1 adrenergic blocker combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor antagonist + selective beta-1 adrenergic blocker combination AT1 receptor (losartan); beta-1 adrenergic receptor (nebivolol) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Losartan and nebivolol (Losartan and nebivolol) — Fondazione IRCCS Policlinico San Matteo di Pavia. This combination reduces blood pressure by blocking angiotensin II receptors (losartan) and slowing heart rate through beta-1 adrenergic blockade (nebivolol).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Losartan and nebivolol TARGET	Losartan and nebivolol	Fondazione IRCCS Policlinico San Matteo di Pavia	phase 3	Angiotensin II receptor antagonist + selective beta-1 adrenergic blocker combination	AT1 receptor (losartan); beta-1 adrenergic receptor (nebivolol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist + selective beta-1 adrenergic blocker combination class)

Fondazione IRCCS Policlinico San Matteo di Pavia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Losartan and nebivolol — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan-and-nebivolol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab